The latest price target for Relmada Therapeutics (NASDAQ:RLMD) was reported by Mizuho on December 5, 2024. The analyst firm set a price target for $1.00 expecting RLMD to rise to within 12 months (a possible 179.17% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Relmada Therapeutics (NASDAQ:RLMD) was provided by Mizuho, and Relmada Therapeutics downgraded their neutral rating.

The last upgrade for Relmada Therapeutics Inc happened on September 17, 2024 when Jefferies raised their price target to $13. Jefferies previously had a hold for Relmada Therapeutics Inc.

The last downgrade for Relmada Therapeutics Inc happened on December 5, 2024 when Mizuho changed their price target from $23 to $1 for Relmada Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a downgraded with a price target of $23.00 to $1.00. The current price Relmada Therapeutics (RLMD) is trading at is $0.36, which is out of the analyst’s predicted range.